“…Interestingly, administration of exogenous NRG1 type III and NRG1 type I promotes neurite outgrowth and nerve regeneration (Mahanthappa et al, 1996; Cai et al, 2004). Moreover, modulation of NRG1 activity in animal models of CMT1A (Fledrich et al, 2014), CMT1B (Scapin et al, 2018) and Congenital Hypomyelinating Neuropathy (Belin et al, 2018), can ameliorate the peripheral hypomyelination observed in these diseases, prevent axonal loss and promote nerve functional recovery, the latter all features observed also after nerve injury. Nonetheless, it has also been recently reported that NRG1 is already highly expressed in nerves of CMT1A pre-clinical models, thus indicating that delivery of exogenous NRG1 should be carefully evaluated (Fornasari et al, 2018).…”